Lena Jendeberg
Director/Miembro de la Junta en ATTANA AB .
Perfil
Lena Jendeberg is currently working as a Director at Attana AB since 2018.
Prior to this, she worked as a Vice President-Development at Modus Therapeutics AB.
Dr. Jendeberg holds a doctorate degree from the Royal Institute of Technology.
Cargos activos de Lena Jendeberg
Empresas | Cargo | Inicio |
---|---|---|
ATTANA AB | Director/Miembro de la Junta | 01/01/2018 |
Antiguos cargos conocidos de Lena Jendeberg.
Empresas | Cargo | Fin |
---|---|---|
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Corporate Officer/Principal | - |
Formación de Lena Jendeberg.
Royal Institute of Technology | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
ATTANA AB | Health Services |
Empresas privadas | 1 |
---|---|
Modus Therapeutics AB
Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Health Technology |
- Bolsa de valores
- Insiders
- Lena Jendeberg